{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:28Z","timestamp":1792979908326,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T00:00:00Z","timestamp":1731110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373956"],"award-info":[{"award-number":["82373956"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Innovation Capability Support Program of Shaanxi","award":["2023-CX-PT-43"],"award-info":[{"award-number":["2023-CX-PT-43"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s10096-024-04977-7","type":"journal-article","created":{"date-parts":[[2024,11,9]],"date-time":"2024-11-09T12:52:19Z","timestamp":1731156739000},"page":"71-82","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Role of letermovir therapeutic drug monitoring for cytomegalovirus prophylaxis in allogeneic hematopoietic stem cell transplantation recipients: a prospective study"],"prefix":"10.1007","volume":"44","author":[{"given":"Yulan","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuqi","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taotao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaojiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuhui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yalin","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,9]]},"reference":[{"key":"4977_CR1","doi-asserted-by":"publisher","first-page":"e919","DOI":"10.1016\/S2352-3026(22)00293-9","volume":"9","author":"Y-J Chang","year":"2022","unstructured":"Chang Y-J, Pei X-Y, Huang X-J (2022) Haematopoietic stem-cell transplantation in China in the era of targeted therapies: current advances, challenges, and future directions. Lancet Haematol 9:e919\u2013e929. https:\/\/doi.org\/10.1016\/S2352-3026(22)00293-9","journal-title":"Lancet Haematol"},{"key":"4977_CR2","doi-asserted-by":"publisher","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","volume":"3","author":"ML Green","year":"2016","unstructured":"Green ML, Leisenring W, Xie H, Mast TC, Cui Y, Sandmaier BM, Sorror ML, Goyal S, \u00d6zk\u00f6k S, Yi J, Sahoo F, Kimball LE, Jerome KR, Marks MA, Boeckh M (2016) CMV viral load and mortality after hematopoietic cell transplantation: a Cohort Study in the era of preemptive therapy. Lancet Haematol 3:e119\u2013e127. https:\/\/doi.org\/10.1016\/S2352-3026(15)00289-6","journal-title":"Lancet Haematol"},{"key":"4977_CR3","doi-asserted-by":"publisher","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","volume":"100","author":"KA Marr","year":"2002","unstructured":"Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002) Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358\u20134366. https:\/\/doi.org\/10.1182\/blood-2002-05-1496","journal-title":"Blood"},{"key":"4977_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","volume":"163","author":"J Piret","year":"2019","unstructured":"Piret J, Boivin G (2019) Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antiviral Res 163:91\u2013105. https:\/\/doi.org\/10.1016\/j.antiviral.2019.01.011","journal-title":"Antiviral Res"},{"key":"4977_CR5","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41409-022-01863-8","volume":"58","author":"S Cesaro","year":"2023","unstructured":"Cesaro S, Ljungman P, Tridello G, Mikulska M, Wendel L, Styczynski J, Averbuch D, de la Camara R (2023) New trends in the management of cytomegalovirus infection after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases Working Pary of EBMT. Bone Marrow Transpl 58:203\u2013208. https:\/\/doi.org\/10.1038\/s41409-022-01863-8","journal-title":"Bone Marrow Transpl"},{"key":"4977_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.3760\/cma.j.issn.0253-2727.2022.08.001","volume":"43","author":"Stem Cell Application Group. Chinese Society of Hematology, Chinese Medical Association","year":"2022","unstructured":"Stem Cell Application Group. Chinese Society of Hematology, Chinese Medical Association (2022) Zhonghua Xue Ye Xue Za Zhi 43:617\u2013623. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2022.08.001","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"4977_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.jtct.2021.05.001","volume":"27","author":"M Hakki","year":"2021","unstructured":"Hakki M, Aitken SL, Danziger-Isakov L, Michaels MG, Carpenter PA, Chemaly RF, Papanicolaou GA, Boeckh M, Marty FM (2021) American Society for Transplantation and Cellular Therapy Series: #3-Prevention of Cytomegalovirus infection and Disease after hematopoietic cell transplantation. Transpl Cell Ther 27:707\u2013719. https:\/\/doi.org\/10.1016\/j.jtct.2021.05.001","journal-title":"Transpl Cell Ther"},{"key":"4977_CR8","doi-asserted-by":"publisher","unstructured":"Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN (2019) Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis 19:e260-e272. https:\/\/doi.org\/10.1016\/S1473-3099(19)30107-0","DOI":"10.1016\/S1473-3099(19)30107-0"},{"key":"4977_CR9","unstructured":"The National Comprehensive Cancer Network (NCCN) (2023) NCCN Guidelines. Prevention and treatment of cancer-related infections Version 2; 2023. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/infections.pdf. Accessed 12 April, 2024"},{"key":"4977_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1002\/psp4.12593","volume":"10","author":"M Prohn","year":"2021","unstructured":"Prohn M, Viberg A, Zhang D, Dykstra K, Davis C, Macha S, Sabato P, de Alwis D, Iwamoto M, Fancourt C, Cho CR (2021) Population pharmacokinetics of letermovir following oral and intravenous administration in healthy participants and allogeneic hematopoietic cell transplantation recipients. CPT Pharmacometrics Syst Pharmacol 10:255\u2013267. https:\/\/doi.org\/10.1002\/psp4.12593","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"4977_CR11","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/cpt.2456","volume":"111","author":"M Prohn","year":"2022","unstructured":"Prohn M, Cho CR, Viberg A, Dykstra K, Davis C, Sabato P, Stone J, Badshah C, Murata Y, Leavitt R, Fancourt C, Macha S (2022) Exposure-response analyses of Letermovir following oral and intravenous administration in allogeneic hematopoietic cell transplantation recipients. Clin Pharmacol Ther 111:485\u2013495. https:\/\/doi.org\/10.1002\/cpt.2456","journal-title":"Clin Pharmacol Ther"},{"key":"4977_CR12","doi-asserted-by":"publisher","first-page":"e0065722","DOI":"10.1128\/aac.00657-22","volume":"66","author":"L Royston","year":"2022","unstructured":"Royston L, Masouridi-Levrat S, Gotta V, Royston E, Pressacco-Brossier C, Abi Aad Y, Tonoli D, Karmime A, Jayo M, Van Delden C, Lescuyer P, Pfister M, Chalandon Y, Neofytos D (2022) Therapeutic drug monitoring of orally administered Letermovir Prophylaxis in Allogeneic hematopoietic stem cell transplant recipients. Antimicrob Agents Chemother 66:e0065722. https:\/\/doi.org\/10.1128\/aac.00657-22","journal-title":"Antimicrob Agents Chemother"},{"key":"4977_CR13","unstructured":"FDA label prevymis \u00ae (letermovir) https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/209939s012,209940s011lbl.pdf"},{"key":"4977_CR14","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2174\/1389200222666210223112826","volume":"22","author":"K Menzel","year":"2021","unstructured":"Menzel K, Kothare P, McCrea JB, Chu X, Kropeit D (2021) Absorption, metabolism, distribution, and excretion of Letermovir. Curr Drug Metab 22:784\u2013794. https:\/\/doi.org\/10.2174\/1389200222666210223112826","journal-title":"Curr Drug Metab"},{"key":"4977_CR15","volume-title":"Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for hematological malignancies","author":"Chinese Society of Clinical Oncology Guidelines Working Committee","year":"2023","unstructured":"Chinese Society of Clinical Oncology Guidelines Working Committee (2023) Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for hematological malignancies. People\u2019s Medical Publishing House, Beijing, China"},{"key":"4977_CR16","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1248\/cpb.c21-00142","volume":"69","author":"T Belabbas","year":"2021","unstructured":"Belabbas T, Yamada T, Tsuchiya Y, Suetsugu K, Egashira N, Ieiri I (2021) Development and full validation of a Bioanalytical Method for quantifying letermovir in human plasma using Ultra-performance Liquid Chromatography coupled with Mass Spectrometry. Chem Pharm Bull 69:646\u2013651. https:\/\/doi.org\/10.1248\/cpb.c21-00142","journal-title":"Chem Pharm Bull"},{"key":"4977_CR17","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1093\/cid\/ciw668","volume":"64","author":"P Ljungman","year":"2017","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, Miller V, Griffiths PD, for the Disease Definitions Working Group of the Cytomegalovirus Drug Development Forum (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis 64:87\u201391. https:\/\/doi.org\/10.1093\/cid\/ciw668","journal-title":"Clin Infect Dis"},{"key":"4977_CR18","doi-asserted-by":"publisher","unstructured":"Girmenia C, Lazzarotto T, Bonifazi F, Patriarca F, Irrera G, Ciceri F, Aversa F, Citterio F, Cillo U, Cozzi E, Gringeri E, Baldanti F, Cavallo R, Clerici P, Barosi G, Grossi P (2019) Assessment and prevention of cytomegalovirus infection in allogeneic hematopoietic stem cell transplant and in solid organ transplant: a multidisciplinary consensus conference by the Italian GITMO, SITO, and AMCLI societies. Clin Transpl 33(e13666). https:\/\/doi.org\/10.1111\/ctr.13666","DOI":"10.1111\/ctr.13666"},{"key":"4977_CR19","unstructured":"National Institutes of Health, National Cancer Institute, U.S (2017) Department of Health and Human Services Common Terminology Criteria for Adverse Events (CTCAE), Version 5.0; 2017. https:\/\/www.nlm.nih.gov\/research\/umls\/sourcereleasedocs\/current\/NCI_CTCAE_5\/index.html. Accessed March 18, 2024"},{"key":"4977_CR20","doi-asserted-by":"publisher","first-page":"122399","DOI":"10.1016\/j.jchromb.2020.122399","volume":"1159","author":"N Isberner","year":"2020","unstructured":"Isberner N, Aghai F, Schirmer D, Kraus S, Grigoleit GU, Klinker H (2020) Quantification of letermovir in human serum using high-performance liquid chromatography with diode array detection. J Chromatogr B Analyt Technol Biomed Life Sci 1159:122399. https:\/\/doi.org\/10.1016\/j.jchromb.2020.122399","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"4977_CR21","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1093\/jpids\/piaa036","volume":"9","author":"N Isberner","year":"2020","unstructured":"Isberner N, Aghai F, Schirmer D, Bolz M, Kraus S, Grigoleit GU, Klinker H (2020) Determination of Letermovir serum levels can be useful in high-risk clinical settings. J Pediatr Infect Dis Soc 9:402\u2013403. https:\/\/doi.org\/10.1093\/jpids\/piaa036","journal-title":"J Pediatr Infect Dis Soc"},{"key":"4977_CR22","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/bcp.15686","volume":"89","author":"B Manczak","year":"2023","unstructured":"Manczak B, Verdier M-C, Dewulf JP, Lemaitre F, Haufroid V, Hantson P (2023) Lactic acidosis after allogeneic haematopoietic stem cell transplantation potentially related to letermovir. Br J Clin Pharmacol 89:1686\u20131689. https:\/\/doi.org\/10.1111\/bcp.15686","journal-title":"Br J Clin Pharmacol"},{"key":"4977_CR23","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y, Brown J, Mullane KM, Boeckh M, Blumberg EA, Einsele H, Snydman DR, Kanda Y, DiNubile MJ, Teal VL, Wan H, Murata Y, Kartsonis NA, Leavitt RY, Badshah C (2017) Letermovir Prophylaxis for Cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433\u20132444. https:\/\/doi.org\/10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"key":"4977_CR24","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1111\/ajt.16450","volume":"21","author":"I Cassaniti","year":"2021","unstructured":"Cassaniti I, Colombo AA, Bernasconi P, Malagola M, Russo D, Iori AP, Girmenia C, Greco R, Peccatori J, Ciceri F, Bonifazi F, Percivalle E, Campanini G, Piccirilli G, Lazzarotto T, Baldanti F (2021) Positive HCMV DNAemia in stem cell recipients undergoing letermovir prophylaxis is expression of abortive infection. Am J Transpl 21:1622\u20131628. https:\/\/doi.org\/10.1111\/ajt.16450","journal-title":"Am J Transpl"},{"key":"4977_CR25","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1177\/1078155218783245","volume":"25","author":"L Geswein","year":"2019","unstructured":"Geswein L (2019) Letermovir associated hepatic transaminitis: a case report. J Oncol Pharm Pract 25:1235\u20131238. https:\/\/doi.org\/10.1177\/1078155218783245","journal-title":"J Oncol Pharm Pract"},{"key":"4977_CR26","doi-asserted-by":"publisher","first-page":"2820","DOI":"10.1093\/jac\/dkz218","volume":"74","author":"V Strenger","year":"2019","unstructured":"Strenger V, Sperl D, Kubesch K, Donnerer J, Schwinger W, Zach K, Lackner H, Benesch M (2019) Letermovir in paediatric HSCT recipients. J Antimicrob Chemother 74:2820\u20132821. https:\/\/doi.org\/10.1093\/jac\/dkz218","journal-title":"J Antimicrob Chemother"},{"key":"4977_CR27","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","volume":"370","author":"RF Chemaly","year":"2014","unstructured":"Chemaly RF, Ullmann AJ, Stoelben S, Richard MP, Bornh\u00e4user M, Groth C, Einsele H, Silverman M, Mullane KM, Brown J, Nowak H, K\u00f6lling K, Stobernack HP, Lischka P, Zimmermann H, R\u00fcbsamen-Schaeff H, Champlin RE, Ehninger G, AIC246 Study Team (2014) Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. N Engl J Med 370:1781\u20131789. https:\/\/doi.org\/10.1056\/NEJMoa1309533","journal-title":"N Engl J Med"},{"key":"4977_CR28","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, Watkins PB, Navarro V, Barnhart H, Gu J, Serrano J, United States Drug Induced Liver Injury Network (2015) Features and outcomes of 899 patients with Drug-Induced Liver Injury: the DILIN prospective study. Gastroenterology 148:1340\u20131352e7. https:\/\/doi.org\/10.1053\/j.gastro.2015.03.006","journal-title":"Gastroenterology"},{"key":"4977_CR29","volume-title":"Clinical and Research Information on Drug-Induced Liver Injury","author":"LiverTox","year":"2012","unstructured":"LiverTox (2012) Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda (MD)"},{"key":"4977_CR30","doi-asserted-by":"publisher","first-page":"572","DOI":"10.19803\/j.1672-8629.2016.09.015","volume":"13","author":"L Sun","year":"2016","unstructured":"Sun L, Guo Q, Zhang H, Tian X, Sun Z (2016) A case of drug-induced liver damage caused by combined use of mezlocillin-sulbactam for injection and cytidine triphosphate disodium. Chin J Pharmacovigil 13:572\u2013574. https:\/\/doi.org\/10.19803\/j.1672-8629.2016.09.015","journal-title":"Chin J Pharmacovigil"},{"key":"4977_CR31","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1080\/17425255.2018.1550485","volume":"14","author":"B Deleenheer","year":"2018","unstructured":"Deleenheer B, Spriet I, Maertens J (2018) Pharmacokinetic drug evaluation of letermovir prophylaxis for cytomegalovirus in hematopoietic stem cell transplantation. Expert Opin Drug Metab Toxicol 14:1197\u20131207. https:\/\/doi.org\/10.1080\/17425255.2018.1550485","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4977_CR32","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1515\/hsz-2016-0259","volume":"398","author":"J M\u00fcller","year":"2017","unstructured":"M\u00fcller J, Keiser M, Drozdzik M, Oswald S (2017) Expression, regulation and function of intestinal drug transporters: an update. Biol Chem 398:175\u2013192. https:\/\/doi.org\/10.1515\/hsz-2016-0259","journal-title":"Biol Chem"},{"key":"4977_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.pharmthera.2018.10.007","volume":"195","author":"S Oswald","year":"2019","unstructured":"Oswald S (2019) Organic Anion transporting polypeptide (OATP) transporter expression, localization and function in the human intestine. Pharmacol Ther 195:39\u201353. https:\/\/doi.org\/10.1016\/j.pharmthera.2018.10.007","journal-title":"Pharmacol Ther"},{"key":"4977_CR34","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1111\/bcp.15677","volume":"89","author":"JB McCrea","year":"2023","unstructured":"McCrea JB, Menzel K, Fancourt C, Witter R, Zhao T, Robbins JA, Stoch SA, Iwamoto M (2023) Evaluation of the inhibitory effects of itraconazole on letermovir. Br J Clin Pharmacol 89:2122\u20132130. https:\/\/doi.org\/10.1111\/bcp.15677","journal-title":"Br J Clin Pharmacol"},{"key":"4977_CR35","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/jcph.1423","volume":"59","author":"JB McCrea","year":"2019","unstructured":"McCrea JB, Macha S, Adedoyin A, Marshall W, Menzel K, Cho CR, Liu F, Zhao T, Levine V, Kraft WK, Yoon E, Panebianco D, Stoch SA, Iwamoto M (2019) Pharmacokinetic drug-drug interactions between Letermovir and the immunosuppressants Cyclosporine, Tacrolimus, Sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol 59:1331\u20131339. https:\/\/doi.org\/10.1002\/jcph.1423","journal-title":"J Clin Pharmacol"},{"key":"4977_CR36","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.taap.2012.03.008","volume":"260","author":"A Crowe","year":"2012","unstructured":"Crowe A, Tan AM (2012) Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux. Toxicol Appl Pharmacol 260:294\u2013302. https:\/\/doi.org\/10.1016\/j.taap.2012.03.008","journal-title":"Toxicol Appl Pharmacol"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04977-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-024-04977-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-024-04977-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T10:46:40Z","timestamp":1737024400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-024-04977-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,9]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["4977"],"URL":"https:\/\/doi.org\/10.1007\/s10096-024-04977-7","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,9]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of the First Affiliated Hospital of Xi\u2019an Jiaotong University (XJTU1AF2023LSK-376), conducted in accordance with the ethical principles of the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}